Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Mälkönen, Tarja; Nuutinen, Pauliina; Hallinen, Taru; Soini, Erkki; Nissinen, Riikka; Wennerström, Christina; Rantanen, Tapio; Hagman, Johanna H.; Harvima, Rauno; Höök-Nikanne, Johanna; Ilves, Tiina; Lintu, Päivi; Malanin, Ken; Soramäki, Iina; Tasanen, Kaisa; Teho, Arja; Vähävihu, Katja; Itälinna, Sari; Leinonen, Pekka; Sarajärvi, Piia; Huilaja, Laura; Pasternack, Rafael (2022)
 
Avaa tiedosto
Lataukset: 



Mälkönen, Tarja
Nuutinen, Pauliina
Hallinen, Taru
Soini, Erkki
Nissinen, Riikka
Wennerström, Christina
Rantanen, Tapio
Hagman, Johanna H.
Harvima, Rauno
Höök-Nikanne, Johanna
Ilves, Tiina
Lintu, Päivi
Malanin, Ken
Soramäki, Iina
Tasanen, Kaisa
Teho, Arja
Vähävihu, Katja
Itälinna, Sari
Leinonen, Pekka
Sarajärvi, Piia
Huilaja, Laura
Pasternack, Rafael
2022


adv00631
doi:10.2340/actadv.v101.910
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202201311719

Kuvaus

Peer reviewed
Tiivistelmä
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.
Kokoelmat